Interim analyses for randomized clinical trials: the group sequential approach
about
Interim analyses of data as they accumulate in laboratory experimentationInterim analyses of survival data in cancer clinical trials.An Ethical Approach to Peeking at Data.ADAPT: the wrong way to stop a clinical trial.Investigating the effect of intra-operative infiltration with local anaesthesia on the development of chronic postoperative pain after inguinal hernia repair. A randomized placebo controlled triple blinded and group sequential study design [NCT00484Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.Group sequential methods and sample size savings in biomarker-disease association studiesPropofol-fentanyl versus propofol alone for lumbar puncture sedation in children with acute hematologic malignancies: propofol dosing and adverse events.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyPhase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.Increasing efficiency of preclinical research by group sequential designs.Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.Adaptive enrichment designs for clinical trialsA review of phase II trial designs for initial marker validation.Sequential analysis applied to clinical trials in dentistry: a systematic review.Two-stage designs in bioequivalence trials.Making what's advanced today routine tomorrow.Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development.Adaptive sampling in two-phase designs: a biomarker study for progression in arthritisInterim analyses and stopping rules in cancer clinical trialsMechanisms of cognitive-behavioral therapy for obsessive-compulsive disorder involve robust and extensive increases in brain network connectivity.Stopping guidelines for an effectiveness trial: what should the protocol specify?Correction of the P-value after multiple coding of an explanatory variable in logistic regression.Piroxicam spares buprenorphine after total joint replacement. Controlled study of pain treatment in 81 patients.Adaptive sample size calculations in group sequential trials.Modification of sample size in group sequential clinical trials.Interim analyses in clinical research.Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective.Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.On the lod score method in linkage analysis.Design of phase I and II clinical trials in cancer: a statistician's view.Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceFuzzy Approach for Group Sequential Test
P2860
Q24799590-BC2C5D87-C033-4B40-9B77-4C11A5D61E20Q30558970-6681004D-12A2-4396-BDBB-DA883EA30F37Q30980303-AE25EC9C-01ED-4AB5-BC35-F568F5E6BFD0Q33263888-73231FD1-6D70-4B18-AD26-5067C96B921AQ33305134-8E3A01AB-92F4-40B9-B4B4-1799B8B2AB74Q33397569-69D47065-EB6B-4D2B-9F95-BC20A864184DQ33923067-824CBAB2-516E-4BEC-9318-BD1B642A83D0Q34133849-A18D103C-782A-4B08-8F26-929B3EFB5D94Q34617224-E1FA3D91-E8CD-4ADF-96EB-15E2F2450DF8Q34793780-529A2C86-DD3F-4D13-AC1B-8A18B8BEB1B0Q35008766-13E4A752-7EA2-4200-AD6A-DAEB777C3A44Q35172814-BB3C7355-A6F9-4B0F-8486-FC6448FEB216Q36304127-D91BC259-A272-404B-832D-87C593B4BC7BQ37059085-FA8B1213-F164-494B-84CB-04AD3DDDC9BCQ37117947-2531BA0A-9D94-4F2D-91E8-E53251A8DDB8Q37162794-3C5D8487-80C4-40A5-92D3-D19201687D08Q37188715-D3C615E9-8029-48E7-BD8D-8F865B378E0EQ37201390-0EBE5A7F-6C04-4F27-A419-DA3879028223Q38325667-649DD42D-D23B-4552-8000-A993CA8E66DEQ38561387-F1711BB0-81A6-4BAE-865B-8BF0BBDC4A8CQ38707747-681427C2-C629-4395-9DBB-3FDCBE32B1CBQ40965192-CB71B4EE-E86F-4E3D-A08A-BEC1D297DD56Q42050766-46ECAB9F-454E-4B5D-8BB9-79E131F0F2B9Q42257159-57789341-B531-4218-82D5-0B5739D96A46Q42800368-0D48943B-E0CE-47D2-8576-93A2C1391646Q43745830-E207AD43-8870-4EC7-BC90-0A7B991384ABQ46755611-80B910CF-2FA8-41E0-B65F-EFCFC51043F4Q47213254-65CF038E-6300-482F-814B-DA1D82E1BAF9Q47213272-55FD18D8-9D37-4943-89B1-4514EE7737C3Q48971413-8727F4A2-9844-492A-B78B-77734A99D7A8Q50697363-86245899-6FC2-4983-8F38-1E8F52EBBDA9Q52061495-4814E019-A28C-4D1B-B524-320F4D3B3A6FQ52687578-1CAF8E4D-D730-4D5D-A357-C1F6D63F7F8DQ52698265-E7C21BF4-09D2-4CC5-9C51-9520A7E84659Q56778031-961E4D73-16E2-42C8-956D-7A507E526670Q59044111-5DF600D2-73FC-4787-8A4D-8DB80CEAB3A1
P2860
Interim analyses for randomized clinical trials: the group sequential approach
description
1982 nî lūn-bûn
@nan
1982 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի մարտին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Interim analyses for randomized clinical trials: the group sequential approach
@ast
Interim analyses for randomized clinical trials: the group sequential approach
@en
Interim analyses for randomized clinical trials: the group sequential approach
@nl
type
label
Interim analyses for randomized clinical trials: the group sequential approach
@ast
Interim analyses for randomized clinical trials: the group sequential approach
@en
Interim analyses for randomized clinical trials: the group sequential approach
@nl
prefLabel
Interim analyses for randomized clinical trials: the group sequential approach
@ast
Interim analyses for randomized clinical trials: the group sequential approach
@en
Interim analyses for randomized clinical trials: the group sequential approach
@nl
P3181
P356
P1433
P1476
Interim analyses for randomized clinical trials: the group sequential approach
@en
P2093
S J Pocock
P304
P3181
P356
10.2307/2530298
P407
P577
1982-03-01T00:00:00Z